
Perspectives from the cutting edge of biotech and pharma. The fast-changing world of biopharma places a premium on trusted market insights from industry experts who can turn change into a competitive advantage. Stay ahead of the curve with our latest podcast series. Lead today. Define tomorrow.
| Publishes | Twice weekly | Episodes | 60 | Founded | 6 years ago |
|---|---|---|---|---|---|
| Number of Listeners | Categories | NewsBusinessBusiness NewsInvesting | |||

Dyne Therapeutics is an early-stage company gearing up for its first launch, promising to tackle unmet need in patients with neuromuscular disease. President and CEO John Cox outlines the science behind the company’s ambitions, and the expansion effo... more
This episode of RBC Pathfinders in Biopharma explores how next-generation retinal gene therapies could transform treatment for patients with wet AMD and diabetic macular edema. CCBO of 4D Molecular Therapeutics, Chris Simms, discusses the promise of ... more
The U.S. administration is keen to sign up more companies to drug pricing deals, and mandatory rules are on the way. But how will the midterm elections affect these and other healthcare policy issues? At RBC’s Global Healthcare Conference, Hunter Ham... more
A growing number of biotechs are defying the perception that you need the might of big pharma to launch a new drug. But there’s always the prospect of an offer that simply can’t be refused. Three leaders who recently sold companies – Whit Bernard (Me... more
People also subscribe to these shows.





Rare to find a podcast focused on the capital markets side of biotech. Very substantive and knowledgeable conversations. Great episode with Omega and Nuvation, keep those coming!
I’m a seasoned angel investor in biotech and I find this podcast really valuable. Every episode has added to my knowledge of both the science and the finance. It fills an important void in the podcast space. Well done team RBC Capital Markets.
Very informative!
I enjoyed every episode, looking forward to more insight.
Key themes from listener reviews, highlighting what works and what could be improved about the show.
How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.
Apple Podcasts | #70 | |
Apple Podcasts | #222 |
Recent interactions between the hosts and their guests.
Listeners, social reach, demographics and more for this podcast.
| Listeners per Episode | |
|---|---|
| Gender Skew | |
| Location | |
| Interests | |
| Professions | |
| Age Range | |
| Household Income | |
| Social Media Reach |
Shows focus on capital markets, investing, and strategic developments in biopharma. Episodes cover sector health, financing trends, M&A, regulatory dynamics, and breakthrough therapies across areas like cancer, psychedelics, retinal diseases, and AI-enabled drug discovery. Noteworthy is the strong investor and RBC Capital Markets lens, bringing high-level financial analysis to scientific and clinical progress, plus guest profiles that span CEOs, CFOs, and top-tier biopharma financiers. This combination offers listeners practical insight for evaluating deals, partnerships, and market timing in a fast-changing industry.
Rephonic provides a wide range of podcast stats for Pathfinders in Biopharma. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to Pathfinders in Biopharma and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.
Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for Pathfinders in Biopharma, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.
Rephonic provides comprehensive predictive audience data for Pathfinders in Biopharma, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.
To see how many followers or subscribers Pathfinders in Biopharma has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.
These podcasts share a similar audience with Pathfinders in Biopharma:
1. BioCentury This Week
2. Biotech Hangout
3. The Readout Loud
4. The Meb Faber Show - Better Investing
5. Exchanges
Pathfinders in Biopharma launched 6 years ago and published 60 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.
Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.
Rephonic pulls ratings and reviews for Pathfinders in Biopharma from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.
View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.
Rephonic provides full transcripts for episodes of Pathfinders in Biopharma. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.
Recent guests on Pathfinders in Biopharma include:
1. Hunter Hammond
2. Will Humphrey
3. Chris Simms
4. Leonid Timashev
5. Rob Barrow
6. George Elston
7. Paris Panayiotopoulos
8. Kabir Nath
To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.